Updates in Cutaneous Oncology

The presentation discusses recent advancements in melanoma treatment, focusing on two key areas: improving patient selection for sentinel node biopsy using gene expression profiling and changes in surgical approaches due to systemic therapies. The indications for sentinel lymph node biopsy remain largely unchanged, primarily relying on tumor thickness. Studies are exploring gene expression profiles to identify patients at low risk for node metastasis, with findings suggesting potential for better patient selection, although these tools haven't fully replaced traditional methods yet. The Merlin O1 trial showed that while low-risk patients had a chance of 7.1% for positive nodes and high-risk patients had 23.8%, neither group could definitively forgo biopsy, pointing to the need for careful clinical evaluation. Additionally, surgical strategies have evolved due to successful immunotherapies, with trials indicating that neoadjuvant therapy prior to surgery yields better outcomes. For operable melanoma with lymph node involvement, a trend towards minimal invasive procedures such as targeted excisions and selective lymph node removals is emerging, which improves recovery and quality of life for patients. The presentation emphasizes the importance of ongoing research to refine these tools and practices.